Sirolimus and Mycophenolate Mofetil (MMF) as Graft Versus Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Transplantation

This study has been terminated.
(First two patients enrolled after trial reopened, developed grade III-IV acute GVHD and subsequently passed away.)
Wyeth is now a wholly owned subsidiary of Pfizer
PDL BioPharma, Inc.
Information provided by (Responsible Party):
Corey S. Cutler, MD, MPH, Dana-Farber Cancer Institute Identifier:
First received: October 23, 2007
Last updated: July 18, 2014
Last verified: July 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2013
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)